Molecular and cellular pharmacologyErythroid differentiation ability of butyric acid analogues: Identification of basal chemical structures of new inducers of foetal haemoglobin
Graphical abstract
Introduction
Several investigations have demonstrated how the clinical status of patients with β-globin disorders can be improved by pharmacologically increased expression of foetal γ-globin genes (Jouini et al., 2012, Musielak, 2011, Huisman, 1979, Stamatoyannopoulos and Nienhuis, 1992, Gallo et al., 1979). Moreover, foetal haemoglobin levels greater than 9% could reduce early mortality (Platt et al., 1994).
A large number of compounds stimulating foetal haemoglobin production, such as chemotherapeutic agents, 5-azacytidine and hydroxyurea (Bunn, 1997, Ferster et al., 1996, Ballas et al., 2006, Italia et al., 2013), was considered; however, citotoxicity, potential carcinogenicity and the moderate effects obtained have limited their clinical use (Domenica Cappellini et al., 2000).
The ability to induce foetal haemoglobin was investigated using several molecules, including hematopoietic growth factors and cytokines. For instance, the effects of erythropoietin and interleukin-3 (IL-3) (Breymann et al., 1999, Reinhardt et al., 2001), as well as the effects of interferon-γ (INF-γ) (Miller et al., 1990) were reported for treatment of the anaemia. In addition, interleukin-4, interleukin-8 and interleukin-18 were found involved with γ-globin gene expression (Kato et al., 2004).
The effects of butyric acid have been investigated since long time in the K562 cell line demonstrating its ability to induce the expression of embryonic globin genes (Cioè et al., 1981). The activity of sodium butyrate and α-amino-n-butyric acid (ABA) to enhance γ-globin synthesis in vitro in erythroid progenitors of patients with sickle cell anaemia and β-thalassaemia, suggested these molecules as relevant for therapy (Perrine et al., 1989). However, there are evidences that the activity of butyric acid and some related compounds can be associated with neurologic toxicity. Therefore, in adult primates, several studies were performed to define the doses able to induce foetal haemoglobin production at lower concentrations and toxic conditions. In addition, the efficacy and toxicity of butyric acid in the presence of other inducers were evaluated (Blau et al., 1993).
In the pharmaceutical field of investigation, butyrates represent a prodrug both to develop less cytotoxic compounds (Faller et al., 1995) and increase aqueous solubility for potential clinical applications (Nudelman et al., 2001). For instance, a novel family of butyric acid (acyloxyalkyl analogues) has been synthetised to increase potency ameliorating transport to the cells (Raphaeli et al., 2000). Among the most studied foetal haemoglobin inducers, histone deacetylase inhibitors (i.e. trichostatin A, arginine butyrate, sodium butyrate, sodium phenylbutyrate) were found to be active in vitro using established cell lines as well as primary erythroid cultures (Glauber et al., 1991, Fibach et al., 1993, Berkovitch-Luria et al., 2012, Muralidhar et al., 2011, Marianna et al., 2001). The interest in applied biomedicine of butyrates is demonstrated by the several patent applications (few examples of this translational activity are US4822821A, US5645852A, EP0627220A1 and the more recent US8618068).
Several studies report in vivo experiments using both mouse (Pace et al., 1996, Partington et al., 1984, Perrine et al., 1988), both primates and humans (Constantoulakis et al., 1989a, Lavelle et al., 1993, Constantoulakis et al., 1988, Fucharoen et al., 2013a, Kutlar et al., 2013) models demonstrating the expected clinical effects of this class of foetal haemoglobin inducers. The activity of sodium butyrate and sodium phenylbutyrate and analogues exhibiting similar mechanism of action have been evaluated in clinical trials (Dover et al., 1994, Sher et al., 1995, Collins et al., 1995, Perrine et al., 2011, Patthamalai et al., 2014) demonstrating induction of foetal haemoglobin in some patients with thalassaemia. A further example in the phase II study made by Domenica Cappellini et al., 2000 made on patients with thalassaemia intermedia treated with oral isobutyramide to evaluate the ability of this butyric acid analogue to stimulate foetal haemoglobin production.
In conclusion, it is well established that the γ-globin gene modulation by butyrate leads to clinically beneficial increasing the endogenous content of foetal haemoglobin. These effects are based on the inhibition of histone deacetylases, causing an accumulation of acetylated histone species in a variety of vertebrate cell lines and hyperacetylation of H3 and H4 (Candido et al., 1978), accompanied with deep modification of the chromatin structure and transcriptional events (Gabbianelli et al., 2000, Gul et al., 2009, Turner and O’Neill, 1995, Turner, 1991).
Since the effects of butyrates have been investigates on K562 cells and on primary erythroid progenitor cells (Cioe et al., 1981, McCaffrey et al., 1997), the in vitro cultures of erythroid precursors represent, in the first step, a model to study haemoglobin production under physiological conditions (Travers et al., 2002, Fibach et al., 2006, Gambari and Fibach, 2007).
The object of our investigation are some analogues presenting chemical structures derivate from a compound described in the U.S. Patent number 5,700,640 (23rd December 1997) (Voss and Caron, 1997) and described in a lot of chemical modification in Fig. 1A.
Section snippets
Compounds employed in the study
The chemical structure of the compound 5049 (Ethyl 4,4,4-trifluoro-butyrate) described in the U.S. Patent number 5,700,640 (23rd December 1997) (Voss and Caron, 1997) and the modified analogues were synthetised by Chiesi Farmaceutici SpA (Parma, Italy) and reported in Fig. 1B. These small molecules are similar to butyric acid, the methyl group replaced with three fluorine atoms producing a fluorinate derivative and the carboxylic esterified with an ethyl group in 5049 compound. The modification
Effects on proliferation and erythroid differentiation of human K562 cells
The growth of K562 cells was analysed after treatment with the investigated compounds for 1, 2 and 5 days. Representative results obtained after 2 days of culture are presented in Fig. 2, where in panel A the growth kinetics of untreated K562 cells untreated and K562 cells treated with the compounds 5049, 5047, 4174, 4145, 4974, 5043 and 5048 are reported. Similarly, in Fig. 2B are indicated the representative cell growth kinetics for the compounds 5124, 5127, 5129, 5128, 5130 and butyric acid.
Discussion
Butyric acid analogues are, together with hydroxyurea, the most used foetal haemoglobin inducers for thalassaemia and sickle cell anaemia therapy (Gambari and Fibach, 2007). The clinical and translational interest on these molecules is demonstrated by several granted patents (a limited examples are US4822821A, US5645852A, EP0627220A1) (Perrine, 1989; Newmark, 1989; Hayhurst et al., 1994). A key example is the recently developed sodium 2,2 dimethylbutyrate (HQK-1001), object of patenting
Aknowledments
Roberto Gambari is funded by Fondazione Cariparo (Cassa di Risparmio di Padova e Rovigo), CIB (Consorzio Interuniversitario per le Biotecnologie), UE THALAMOSS Project (Thalassemia Modular Stratification System for Personalized Therapy of Β-Thalassemia; No. 306201-FP7-HEALTH-2012-INNOVATION-1), Telethon (Contract GGP10124) and by COFIN-2010. This research activity was also supported by Associazione Veneta per la Lotta alla Talassemia (AVLT), Rovigo and by AIRC-2012. We thank Dr. Dino Martello
References (82)
- et al.
A multifunctional 5-aminolevulinic acid derivative induces erythroid differentiation of K562 human erythroleukemic cells
Eur. J. Pharm. Sci.
(2012) - et al.
Short-chain fatty acid-mediated effects on erythropoiesis in primary definitive erythroid cells
Blood
(2009) - et al.
Fetal hemoglobin induction with butyric acid: efficacy and toxicity
Blood
(1993) - et al.
Abrogation of IL-3 requirements and stimulation of hematopoietic cell proliferation in vitro and in vivo by carboxylic acids
Blood Cells Mol. Dis.
(1997) - et al.
The effects of cyclopropane carboxylic acid on hepatic pyruvate metabolism
Metab. Clin. Exp.
(1983) - et al.
Sodium butyrate inhibits histone deacetylation in cultured cells
Cell
(1978) - et al.
Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial
Blood
(1995) - et al.
On the induction of fetal hemoglobin by butyrates: in vivo and in vitro studies with sodium butyrate and comparison of combination treatments with 5-AzaC and AraC
Blood
(1989) - et al.
alpha-Amino-N-butyric acid stimulates fetal hemoglobin in the adult
Blood
(1988) - et al.
Oral isobutyramide therapy in patients with thalassemia intermedia: results of a phase II open study
Blood Cells Mol. Dis.
(2000)
Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate
Blood
Differences in response to fetal hemoglobin induction therapy in beta-thalassemia and sickle cell disease
Blood Cells Mol. Dis.
Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial
Blood
Mithramycin induces fetal hemoglobin production in normal and thalassemic human erythroid precursor cells
Blood
Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia
Blood
Hemoglobin switching in unicellular erythroid culture of sibling erythroid burst-forming units: kit ligand induces a dose-dependent fetal hemoglobin reactivation potentiated by sodium butyrate
Blood
Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome
Blood
Induction of gamma-globin by histone deacetylase inhibitors
Blood
Histone deacetylase 9 activates gamma-globin gene expression in primary erythroid cells
J. Biol. Chem.
Eur. J. Med. Chem.
In vivo search for butyrate responsive sequences using transgenic mice carrying A gamma gene promoter mutants
Blood
A phase 2 trial of HQK-1001 in HbE-β thalassemia demonstrates HbF induction and reduced anemia
Blood
Targeted fetal hemoglobin induction for treatment of beta hemoglobinopathies
Hematol. Oncol. Clin. N. Am.
The human bladder carcinoma cell line 5637 constitutively secretes functional cytokines
Leuk. Res.
Augmentation of gamma-globin gene promoter activity by carboxylic acids and components of the human beta-globin locus control region
Blood
Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells
Blood
The effects of cyclopropane carboxylate on hepatic pyruvate metabolism
Arch. Biochem. Biophys.
Human CD34+ hematopoietic progenitor cells hyperacetylate core histones in response to sodium butyrate, but not trichostatin A
Exp. Cell Res.
Histone acetylation in chromatin and chromosomes
Semin. Cell Biol.
Hydroxyurea and sickle cell anemia: effect on quality of life
Health Qual. Life Outcomes
Accumulation of gamma-globin mRNA and induction of erythroid differentiation after treatment of human leukaemic K562 cells with tallimustine
Br. J. Haematol.
On the formation of a peculiar benzidine-positive band in incubation in vitro of different hemoglobins with various plasmas
Boll. Soc. Ital. Biol. Sper.
Induction of fetal hemoglobin synthesis with recombinant human erythropoietin in anemic patients with heterozygous beta-thalassemia during pregnancy
J. Matern. Fetal Med.
Pathogenesis and treatment of sickle cell disease
N. Engl. J. Med.
Differential expression of the globin genes in human leukemia K562(S) cells induced to differentiate by hemin or butyric acid
Cancer Res.
Butyrate stimulates HbF in adult baboons
Prog. Clin. Biol. Res.
Butyrate in the treatment of sickle cell disease and [beta]-thalassemia
Curr. Opin. Hematol.
Induction of fetal hemoglobin in the treatment of sickle cell disease
Hematol. Am. Soc. Hematol. Educ. Program
Effects of rapamycin on accumulation of alpha-, beta- and gamma-globin mRNAs in erythroid precursor cells from beta-thalassaemia patients
Eur. J. Haematol.
Resveratrol: antioxidant activity and induction of fetal hemoglobin in erythroid cells from normal donors and β-thalassemia patients
Int. J. Mol. Med.
A randomized phase I/II trial of HQK-1001, an oral fetal globin gene inducer, in β-thalassaemia intermedia and HbE/β-thalassaemia
Br. J. Haematol.
Cited by (6)
The state of the art of fetal hemoglobin-inducing agents
2022, Expert Opinion on Drug DiscoveryHemoglobin F (HbF) Inducers; History, Structure and Efficacies
2022, Mini-Reviews in Medicinal ChemistryGeneration of an in vitro model of β-thalassemia using the CRISPR/Cas9 genome editing system
2020, Journal of Cellular BiochemistryTreatment of erythroid precursor cells from β‐thalassemia patients with cinchona alkaloids: Induction of fetal hemoglobin production
2021, International Journal of Molecular Sciences